PressJuly 20, 2023 Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
PressJuly 20, 2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast
PressJuly 20, 2023 Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
PressJuly 20, 2023 PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
PressJuly 20, 2023 Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering of Up To C$2,000,000
BusinessJuly 19, 2023 UC Berkeley Survey: Understanding Voter Attitudes Towards Psychedelic Legalization
PressJuly 18, 2023 PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
PressJuly 17, 2023 Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
PressJuly 17, 2023 COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
PressJuly 17, 2023 Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
PressJuly 17, 2023 Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
PressJuly 14, 2023 Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
PressJuly 14, 2023 Beckley Retreats Advances Research to Combat Veteran Suicide Through Psychedelic Retreats
PressJuly 14, 2023 Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
PressJuly 14, 2023 BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
PROJuly 13, 2023 Breaking Boundaries, Transforming Markets: A Comprehensive Mid-Year Review of the Psychedelic Sector (PRO REPORT)
PressJuly 12, 2023 Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
